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Patterns of metastasis in colon and 
rectal cancer
Matias Riihimäki1,2, Akseli Hemminki3,4, Jan Sundquist2 & Kari Hemminki1,2
Investigating epidemiology of metastatic colon and rectal cancer is challenging, because cancer 
registries seldom record metastatic sites. We used a population based approach to assess metastatic 
spread in colon and rectal cancers. 49,096 patients with colorectal cancer were identified from the 
nationwide Swedish Cancer Registry. Metastatic sites were identified from the National Patient 
Register and Cause of Death Register. Rectal cancer more frequently metastasized into thoracic organs 
(OR = 2.4) and the nervous system (1.5) and less frequently within the peritoneum (0.3). Mucinous 
and signet ring adenocarcinomas more frequently metastasized within the peritoneum compared 
with generic adenocarcinoma (3.8 [colon]/3.2 [rectum]), and less frequently into the liver (0.5/0.6). 
Lung metastases occurred frequently together with nervous system metastases, whereas peritoneal 
metastases were often listed with ovarian and pleural metastases. Thoracic metastases are almost as 
common as liver metastases in rectal cancer patients with a low stage at diagnosis. In colorectal cancer 
patients with solitary metastases the survival differed between 5 and 19 months depending on T or N 
stage. Metastatic patterns differ notably between colon and rectal cancers. This knowledge should help 
clinicians to identify patients in need for extra surveillance and gives insight to further studies on the 
mechanisms of metastasis.
Colorectal cancer (CRC) is the third most common cancer worldwide1. Approximately 56% of patients with CRC 
die from their cancer2. Development of metastasis is a concern for patients and clinicians alike as metastasis may 
be fatal, causing mass-effect and meddling with homeostasis3–5. Approximately 20% of patients with CRC already 
have metastases at diagnosis, and this figure has been stable over the last two decades6. With the help of contin-
uous developments in CRC treatment, survival rates have improved. Metastatic disease has previously has been 
viewed as incurable. However, in favorable settings median survival may surpass five years in patients with soli-
tary lung or liver metastases7–9. Detecting CRC early is vital considering the negative effect on survival conferred 
by already metastatic cancer6,10. Although current evidence has shown a decreased cancer specific mortality from 
CRC in screening groups, all-cause mortality may not be improved by screening11.
Recent progress in metastasis research has vastly expanded our understanding of metastasis on the cellular 
and molecular level3,4,12,13. Unfortunately, knowledge at the epidemiological level is lacking. Efforts to investigate 
metastases are hampered by the fact that cancer registries seldom include any information on metastases apart 
from the stage at diagnosis. In this setting, it is impossible to assess metastatic spread to specific sites. Overviews 
of metastatic patterns across different cancers are limited to autopsy-based studies relying on approximately one 
thousand deaths from metastatic cancer14–16. Although these reports are impressive and important, it may not be 
easy to discuss magnitude of clinically relevant metastases based on autopsies. Apart from a recent Dutch study6, 
most available reports of CRC metastases are either based on single hospital series or subnational registers17,18. An 
alternate approach would be to investigate the causes of death in cancer, as both hospital-based registers and cause 
of death registers are based on the International Classification of Diseases (ICD). In the present study, we used 
information from two Swedish nationwide registers, the National Patient Register and Cause of Death Register. 
We investigated the patterns of metastasis from colon and rectal cancer to specific sites, depending on sex, age at 
diagnosis, histological subtype, stage, number of metastases, and whether the primary was situated in proximal 
or distal colon, or in the rectum. We also estimated survival depending after diagnosis of colon and rectal cancer 
with distant metastasis.
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Methods
This study utilized data form several linked nationwide registers in Sweden. The Swedish Family-Cancer Database 
includes cancer data from the Swedish Cancer Register, encompassing cancers diagnosed in Sweden since 1958. 
Furthermore, death causes are included from the Cause of Death Registry, as well as vital statistics19. The primary 
sites are coded by ICD’s 7th revision in the Cancer Registry. Patients with CRC were identified with codes 153 
and 154.0. Then anatomical location is known through the ICD code (proximal colon [153.0/.1], distal colon 
[153.2/.3], and rectum [154.0]). SNOMED histological codes and is included since 1993. We identified patients 
with the histological subtypes signet-ring adenocarcinoma and mucinous adenocarcinoma by the SNOMED 
codes 8480 and 8490, whereas generic adenocarcinomas are listed under the code 8140. Cancers were staged 
I-IV depending on the TNM (Tumor, lymph Node, distant Metastasis) stage. T-stages “T1” and “T2” were stage 
I, whereas T-stages “T3” and “T4” were stage II. Irrespective of T stage, positive lymph node status (N1, N2) was 
stage III and occurrence of distant metastases (M1) was stage IV. TNM staging is included since 2002, and is not 
downgraded by neoadjuvant therapy. Analysis was therefore restricted to patients diagnosed with colon or rectal 
cancers in years 2002 through 2012. Follow-up on metastatic information was available until the end of 2012. 
Patients with multiple primary cancers were excluded.
Metastatic involvement was identified from the National Patient Register and Cause of Death Register. In the 
National Patient Register, metastases can either be listed as the main diagnosis or as one of up to 21 accompany-
ing diagnoses during the hospitalization. Data from all hospitalizations in Sweden are included in the National 
Patient Register, which reached nationwide coverage in 198720. Reporting is obligatory in both public and private 
healthcare facilities. Alternate sources of metastatic data were causes of death. These were identified from the 
national Cause of Death Registry, where the underlying causes and up to 10 accompanying causes of death are 
listed. Since 1996, both registers implement coding through ICD-10. The codes used for identifying metastatic 
sites were as follows: lung (C78.0), pleura (C78.2), other respiratory organs (C78.1/.3), peritoneum (C78.6), liver 
(C78.7), other gastro-intestinal (C78.4/.5/.8), urinary system (C79.0/.1), skin (C79.2), nervous system (C79.3/.4), 
bone (C79.5), ovary (C79.6), adrenal (C79.7), other specified (C79.8). The last-mentioned group cannot be spec-
ified further, but it includes metastases to genital organs and breast tissue. Metastases to “ill-defined” sites or 
unspecified sites were not included in this analysis, nor were patients with unknown anatomical site or histology. 
Although nodal metastases are important for staging, these were excluded due to their small number and to limit 
the size of this study. In certain analyses, rare sites of metastases (skin, ovary, adrenal, and other specified) were 
grouped together as “other metastasis”. Due to the small frequencies, these sites were analyzed together as one 
group.
A multivariable logistic regression model was used to calculate odds ratios (OR) for sex, age, anatomical site, 
and histological type on specific metastases. P-values for 2 × 2- tables were obtained by using chi-square test. 
Survival in metastatic colon and rectal cancers was investigated with a multivariable Cox regression model, yield-
ing hazard ratios (HR). This model adjusted for sex, age, anatomical site, histological type, and stages T and N. All 
calculations were performed using SAS software, version 9.3.
Results
A flow chart depicts the selection of patients (Fig. 1). The number of patients, sex, histological subtype, and stage 
are summarized in Table 1. We identified 49,096 patients, 31,285 with colon cancer and 17,811 with rectal cancer. 
Of these, 9,364/5,601 (30% colon/31% rectum) had a recorded metastasis. Of them, 5,210/2,780 had a single 
metastasis. Metastases were obtained from the National Patient Register (8,691/5,164) and the Cause of Death 
Register (3,910/2,297). Mucinous and signet ring adenocarcinoma were more common in women and in patients 
with proximal colon cancer. The overall median age at diagnosis was 72.4 years. Patients with proximal colon can-
cer had the highest age at diagnosis, while rectal cancer patients had the lowest. 83% of all stage IV colorectal can-
cer patients diagnosed 2002 through 2012 had site specific metastases. Furthermore, 2,613 patients (5% of total) 
without specified extranodal metastases had metastases to lymph node, ill-defined, or unspecific sites. Of these, 
442 were patients with stage IV cancer. Also, 5% had not died during the follow-up time, thus lacking the causes 
of death. Therefore, the underreporting in the combined registers can be assumed to be maximally only 7% for the 
stage IV disease, and we find no reason to believe why this underreporting would be anything else than random.
We described the relative frequency of specific metastases depending on the stage at diagnosis and the number 
of listed metastases, separately for colon or rectal cancers. The complete data can be found in Supplemental Table 1 
(colon cancer) and 2 (rectal cancer). Thoracic, liver, and peritoneal metastases have been selected to be depicted 
in Fig. 2. In patients with single metastases, the relative frequency of thoracic metastases was higher in lower 
stages (p-value for difference < 0.0001 in both two comparisons), especially in rectal cancer. However, there was 
no significant difference in the frequency of patients with thoracic metastases among those with multiple metas-
tases. This is opposite to liver metastases, which were relative more frequent with higher stage irrespective of sex, 
anatomical sites, or the number of metastases (p-value < 0.0001 in all 6 comparisons). The relative frequency 
of peritoneal metastases was more stable across stages and numbers of metastases. Nervous system and bone 
metastases had a similar trend as thoracic metastases. They were uncommon as single metastases in patients with 
high stage (1%) but significantly more common as single metastases in patients at lower stages. As many as 10% 
of patients with single metastases from stage I colon cancer had bone metastasis.
Table 2 gives multivariable ORs for colon cancer patients to have metastatic spread to a single location. 
Women had a lower OR to develop liver (OR= 0.80 [95% CI: 0.73–0.91]) and bone metastases (0.36) compared to 
men. For most sites, younger patients had a higher risk. Mucinous and signet ring adenocarcinomas had a lower 
risk of liver metastases (0.48 [0.41–0.57]) but a higher risk of peritoneal metastases (3.80 [3.18–4.55]). Distal 
colon cancer was associated with an increased risk of thoracic metastases.
Compared with colon cancer, rectal tumors (Table 3) spread significantly more frequently to the thorax 
(2.41 [2.12–2.75]), the bone (1.38 [1.08–1.77]), and the nervous system (1.49 [1.09–2.04]), but less likely in the 
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peritoneum (0.33 [0.27–0.40]). As in colon cancer, women with rectal cancer had a fewer metastases to the liver 
(0.77 [0.70–0.86]). The differences between age and histological type were similar as in colon cancer: increased 
age was associated with less peritoneal and liver metastases, although no difference in thoracic metastases could 
be detected.
In Supplemental Tables 3 and 4, the spread of metastases from colon and rectal cancers is shown, irrespective 
of their number of metastases. As more metastases are included in the analysis, the differences between patient 
characteristics become less pronounced. Of all patients with metastatic cancer, the most common sites of metasta-
sis were the liver (70% in colon cancer/70% in rectal cancer) and the thorax (32%/47%). In colon cancer, the third 
most common site was the peritoneum (21%) whereas in rectal cancer it was the bone (12%). Nervous system 
metastases were present in 5% of colon cancer, and in 8% of rectal cancer.
Table 4 addresses patients with multiple metastases. Liver metastases were most frequently solitary metastases 
(in 48% of colon/45% of rectal cancer), whereas the percentages were substantially lower for other metastatic 
locations. Lung metastases often occurred together with liver metastases (73%/63%). Liver metastases were less 
frequent among patients with peritoneal (48%/52%) or nervous system metastases (53%/46%). In contrast, lung 
metastases were often present in patients with nervous system metastases (54%/65%).
Survival in metastatic CRC is depicted in Table 5 for patients with a single metastatic site. The HRs were worst 
for old patients (2.40 [2.12–2.72] for those diagnosed at age > 79 years vs. 1.00 for age < 60 years), for metastatic 
locations in the nervous system (1.73 [1.21–2.49]) or the bone (1.56 [1.13–2.16]) compared the liver (1.00) or the 
thorax (0.64 [0.55–0.76]), and for proximal colon (1.42 [1.29–1.56] vs. 1.00 for the rectum). Median survival for 
patients with liver metastases (9 months) was shorter than for those with thoracic metastases (14 months); the 
survival was worst for rare patients with sole nervous system (4 months) or bone (5.5 months) metastases. The 
T and N stages strongly influenced survival. Patients with T2 survived 16.5 months compared to those with T4 
(8 months) or TX (5 months). Patients with N0 survived 19 months compared to those with N2 (8 months) or NX 
(5 months). Results did not differ if all stage IV patients were considered, irrespective of the number of metastases 
(data not shown).
Ethical Approval. This study was approved by the ethical committee at Lund University, Sweden.
Discussion
In this paper, we investigated metastatic patterns in colon and rectal cancers and presented results from nation-
wide Swedish registers. Significant variations could be noted between anatomical sites of primary cancer and its 
histological subtypes. These patterns have not been described earlier to this extent and address questions regard-
ing the nature of metastatic spread and biology of metastases. Although the prognosis is indeed already dire in 
Figure 1. Flow chart depicting the selection of patients. 
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metastatic colon and rectal cancers, the site of distant metastasis was an important prognostic factor. Also, T- and 
N-stage had a huge impact on survival, and depending on these factors the median survival could range between 
5 and 19 months. Therefore, stage IV cancer should not be considered as a single entity. Overall, median survival 
after diagnosis of colon or rectal cancer was 10 months, which is in line with previous observations6.
The “anatomical/mechanical” and “seed-and-soil” hypotheses are widely accepted to explain metastatic 
spread3,5,21,22. Recent developments have refined the seed-and-soil hypothesis to new levels, because it has been 
possible to investigate tumor-stroma interactions at a molecular level. Specific tumor cells may show a prefer-
ence to specific target organs of metastasis23–25. For example, small cell lung cancer is more prone to metastasize 
to the liver than other histological types5. Previous autopsy based studies have put forward theories about the 
cascadic spread of gastro-intestinal tumors21,22. Metastases at the first draining site may act as seeds to further 
metastasis. From the colon and proximal parts of the rectum, blood is drained through the portal system to the 
liver. From the liver the next organ is the lungs, via the heart. The distal parts of the rectum surpass the liver, 
and the first encountered organ is the lungs. Therefore it seems logical that we observed that rectal cancer more 
frequently metastasized to thoracic organs than colon cancer, which is in line with previous suggestions6,18. Also, 
all sites in the gastro-intestinal system share a common lymphatic drain, flowing via the cisterna chyli to the 
left subclavian vein, and to the lungs. Adding to the complexity, metastases may spread through the peritoneal 
fluid within the peritoneal cavity. Mucinous adenocarcinomas showed excessive metastasizing within the peri-
toneum. The production of mucus may enable access to the peritoneal space26. Mucinous adenocarcinomas are 
thought of to be more aggressive. This may enhance growth in the peritoneal lining as soon as the peritoneum 
is accessed, although it is also possible that mucinous adenocarcinomas may have a genetic advantage to growth 
Men Women
N % Age N % Age
Proximal colon
All 7969 31% 73 9754 42% 76
Stage
 I 867 11% 74 1034 11% 77
 II 2451 31% 75 3050 31% 77
 III 2076 26% 73 2691 28% 76
 IV 1366 17% 70 1533 16% 73
 Unknown 1209 15% 74 1446 15% 77
Histology
 AD* 7123 89% 73 8543 88% 76
 SR/MC** 846 11% 73 1211 12% 77
Distal colon
All 7367 29% 71 6195 27% 72
Stage
 I 1069 15% 72 968 16% 73
 II 1908 26% 73 1571 25% 74
 III 1769 24% 70 1456 24% 70
 IV 1358 18% 69 1076 17% 68
 Unknown 1263 17% 73 1124 18% 74
Histology
 AD 6911 94% 71 5733 93% 72
 SR/MC 456 6% 69 462 7% 72
Rectum
All 10477 41% 70 7334 31% 72
Stage
 I 1941 19% 70 1484 20% 71
 II 2085 20% 70 1339 18% 72
 III 2262 22% 69 1662 23% 70
 IV 1720 16% 68 1078 15% 70
 Unknown 2469 24% 72 1771 24% 75
Histology
 AD 10036 96% 70 7031 96% 72
 SR/MC 441 4% 69 303 4% 72
 Total (Row %) 25813 100% 71 23283 100% 74
Table 1.  Distribution of stage, histological type, and median age at diagnosis (years) by anatomical site, 
and sex in 49,096 patients with colon or rectal cancer. * AD = Adenocarcinoma. * * SR/MC = signet  
ring/mucinous adenocarcinoma.
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in the peritoneal cavity. Although the differences between colon and rectal cancer were striking, there were also 
notable differences between the proximal and distal colon, clearly demonstrating their different biology. The 
proximal colon originates form the midgut, whereas the distal colon stems from the hindgut. The two entities 
vary in e.g. epidemiology, biology, and genetics27.
Our findings regarding multiple metastases are important to understand the spread of metastases. Respiratory 
metastases were indeed more common in patients who also had metastases into bone or the nervous system, 
whereas respiratory metastases were infrequent together with peritoneal metastasis and other gastro-intestinal 
sites. Most patients with respiratory metastases also had liver metastases. Some distinct patterns can be recog-
nized. It appears that CRC spreads via the portal circulation to the liver, and from there to the lungs. It may also 
reach the lungs directly, perhaps using lymphatics, or directly from the distal rectum. However, in the present 
data there were clear indications that the lungs seem to be an important waypoint toward further spread: nervous 
system metastases occurred more frequently together with respiratory metastases than with liver metastases. One 
speculation is that tumors metastasizing through the “normal” portal route are less mobile than more adven-
turous cells able to seek the lungs or the central nervous system. Further studies are clearly needed, but perhaps 
the latter class of cells represents classic cancer stem cells better than the more passive tumor initiating cells 
Figure 2. Frequency of thoracic, liver, and peritoneal metastases in patients with colon or rectal cancer, 
depending on how many metastases were present and the stage of patients. Black line: one metastasis, gray 
line: two metastases, dotted line: three or more metastases.
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which just end up in the liver with the blood flow. CRC may metastasize within the abdominal cavity, giving rise 
to non-hematogenous ovarian metastases, which were frequently detected together with peritoneal metastases, 
especially in colon cancer. This is logical as the peritoneum and ovaries are often considered a continuum espe-
cially in the context of primary cancer of these organs. Furthermore, ovarian metastases were substantially more 
common among women with colon than rectal cancer, which may be due to anatomic factors as the intestine 
leaves the peritoneal double bag about midway through the rectum.
Recent research on the immunology of cancer has provided intriguing insight into the metastatic process, 
and may help us further understand the difference between thoracic and liver metastases. In the present study, 
many CRC patients presented with extrahepatic metastases and without detectable liver metastases. As discussed 
above, anatomical factors may be an explanation. However, one could hypothesize that liver metastases have 
indeed been present, but have been eliminated or entered a dormant phase, rendering treatment ineffective12. At 
lower stages, thoracic metastases were almost as frequent as liver metastases, and also in stage IV patients with 
multiple metastases. The only group where liver metastases were clearly more common was in stage IV patients 
with single metastases. Similar findings were reported in a recent Japanese hospital study28, where lung metas-
tases were more frequent in CRC patients who underwent curative surgery, compared with stage IV patients. 
Therefore, it seems that lung metastases need a longer time to grow, compared with liver metastases. This is not 
Patient 
characteristics
Any 
metastasis Thorax Peritoneum Liver
Other Gastro-
intestinal Nervous system Bone Other
OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI
All 8% 4% 62% 5% 2% 3% 8%
Sex
 Men 1 8% 1 12% 1 64% 1 4% 1 2% 1 4% 1 7% 1
 Women 0.9 0.8 0.9 8% 0.9 0.7 1.1 14% 1.1 0.9 1.3 59% 0.8 0.7 0.9 5% 1.2 0.9 1.5 2% 1.1 0.7 1.7 2% 0.4 0.3 0.5 10% 1.3 1.1 1.6
Age at diagnosis
 <60 1 7% 1 17% 1 62% 1 4% 1 1% 1 3% 1 4% 1
 60–69 0.9 0.8 1.0 7% 1.0 0.7 1.4 13% 0.7 0.6 0.9 64% 0.9 0.8 1.1 4% 1.0 0.7 1.6 1% 1.5 0.6 3.3 3% 1.0 0.6 1.7 5% 1.1 0.8 1.6
 70–79 0.8 0.7 0.8 10% 1.2 0.9 1.6 11% 0.5 0.4 0.6 62% 0.8 0.7 0.9 5% 1.0 0.7 1.5 2% 1.5 0.7 3.4 3% 0.9 0.6 1.5 5% 1.0 0.7 1.3
 >79 0.6 0.6 0.7 10% 1.1 0.8 1.5 11% 0.4 0.3 0.6 59% 0.6 0.6 0.7 4% 0.7 0.5 1.1 2% 1.6 0.7 3.6 3% 0.9 0.5 1.6 10% 1.0 0.7 1.4
Anatomical site
 Proximal colon 1 7% 1 13% 1 61% 1 5% 1 2% 1 3% 1 8% 1
 Distal colon 1.1 1.0 1.2 10% 1.4 1.2 1.7 13% 1.1 0.9 1.3 62% 1.1 1.0 1.1 4% 0.7 0.5 0.9 1% 0.6 0.4 0.9 3% 1.1 0.8 1.5 9% 1.2 1.0 1.5
Histology
 Adenocarcinoma 1 8% 1 10% 1 64% 1 4% 1 2% 1 3% 1 8% 1
  Signet ring/
Mucinous AD 0.9 0.8 1.0 8% 0.9 0.6 1.3 39% 3.8 3.2 4.5 35% 0.5 0.4 0.6 5% 0.7 0.4 1.2 2% 0.7 0.3 1.6 3% 1.1 0.6 1.9 11% 1.3 1.0 1.8
Table 2.  Multivariable logistic regression model for odds for specific metastases in colon cancer patients 
with a single metastasis. The model adjusts for sex, age at diagnosis, anatomical site, and histological type. Bold 
values indicate significantly higher odds, and underlined values indicate significantly lower odds.
Patient 
characteristics
Any 
metastasis Thorax Peritoneum Liver
Other Gastro-
intestinal Nervous system Bone Other
OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI % OR 95% CI
All (OR rectum vs. 
colon) 1.0 0.9 1.0 19% 2.4 2.1 2.7 4% 0.3 0.3 0.4 61% 0.9 0.9 1.0 2% 0.4 0.3 0.6 3% 1.5 1.1 2.0 4% 1.4 1.1 1.8 7% 0.9 0.8 1.1
Sex
 Men 1 18% 1 4% 1 65% 1 2% 1 3% 1 4% 1 5% 1
 Women 0.9 0.8 1.0 22% 1.2 1.0 1.4 4% 1.1 0.8 1.6 55% 0.8 0.7 0.9 2% 0.7 0.4 1.1 3% 0.9 0.6 1.4 3% 0.7 0.5 1.0 11% 1.9 1.4 2.5
Age at diagnosis
 <60 1 15% 1 5% 1 65% 1 1% 1 3% 1 7% 1 16% 1
 60–69 0.9 0.8 1.0 18% 1.1 0.9 1.5 4% 0.7 0.4 1.1 66% 0.9 0.8 1.1 1% 0.4 0.2 1.2 4% 0.7 0.4 1.5 6% 0.9 0.5 1.6 15% 0.7 0.5 1.1
 70–79 0.8 0.7 0.9 22% 1.2 0.9 1.6 4% 0.8 0.5 1.3 57% 0.7 0.6 0.8 3% 1.4 0.7 3.1 4% 1.2 0.6 2.2 6% 1.1 0.6 1.8 14% 0.7 0.5 1.1
 >79 0.7 0.6 0.8 22% 1.1 0.8 1.4 3% 0.5 0.3 0.9 54% 0.6 0.5 0.7 3% 1.8 0.8 3.9 5% 0.7 0.3 1.4 11% 1.1 0.6 1.9 16% 1.0 0.7 1.5
Histology
 Adenocarcinoma 1 19% 1 4% 1 62% 1 2% 1 3% 1 4% 1 7% 1
 Signet ring/
Mucinous AD 1.0 0.8 1.2 20% 1.0 0.7 1.5 11% 3.2 1.8 5.6 42% 0.6 0.5 0.9 2% 1.3 0.4 4.1 1% 0.3 0.0 2.2 7% 1.9 1.0 3.8 16% 2.5 1.6 4.0
Table 3.  Multivariable logistic regression model for odds of specific metastases in rectal cancer patients 
with a single metastasis. The model adjusts for sex, age at diagnosis, and histological type. Bold values indicate 
significantly higher odds, and underlined values indicate significantly lower odds.
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an unaccustomed thought, because the liver is considered an immunosuppressive organ29 and survival in liver 
metastases was indeed poor, only 9 months. If the metastasis succeeds in escaping the immune system, the milieu 
of the liver will promote the growth of liver metastases, which thus will become clinically apparent. Metastases 
to other sites have yet not occurred, at least at a clinically detectable rate. The relatively better prognosis in tho-
racic metastases implies a slower growth rate, which is compatible with retained activity of anti-tumor immune 
responses. Improvements in radiological methods have enabled detection of event smaller tumor growths, e.g. 
lung metastases6,18.
In many patients, spread to the lung coincides with further metastases to the nervous system or bone, with 
many clinical implications. For example, the brain is not normally imaged in routine evaluation of CRC patients, 
regardless of metastasis location. Diagnosis of brain and bone metastases is not for intellectual interest only; it 
has direct links to treatment selection. Brain metastases can be treated with whole brain or stereotactic irradia-
tion; the latter is more attractive if the metastases are found early30. For prevention of bone metastasis associated 
fractures, bisphosphonates are available31. Patients with sole liver metastases dominating could represent a tumor 
immunologically distinct from those cases where tumor load is smaller and lung and bone metastases are present. 
These findings could have immediate clinical implications also with regard to the recent breakthrough of check-
point inhibiting antibodies32. If the subsets proposed here are immunologically distinct, they may respond to 
checkpoint inhibitors. There are much recent data indicating that “the Immunoscore” is quite relevant in CRC33. 
Our findings provide further hints that not all colorectal tumors are alike immunologically or metastatically.
An unfortunate shortcoming in most population based analyses, including ours, is the lack of diagnostic and 
other clinical data. This includes for example imaging, comorbidities, or molecular profiling. Also, we cannot con-
sider the effect of treatment received. Our inclusion of death certificates is an important strength over previous 
reports, because we can thereby access those cancer patients who died from indeed clinically relevant metastases 
but were not hospitalized for unknown reasons.
Site of 
metastasis
Total 
amount
As one of N listed 
metastases % 
multiple Lung
Pleura/
Mediastinum Peritoneum Liver
Other 
G-I
Urinary 
system Skin
Nervous 
system Bone Adrenal Ovary* Other1 2 3 4+
COLON
Lung 2881 410 1406 718 347 86% 100% 5% 15% 73% 7% 1% 1% 8% 11% 3% 2% 11%
Pleura/
Med. 260 16 75 82 87 94% 54% 100% 30% 60% 11% 2% 1% 10% 12% 2% 2% 18%
Peritoneum 2000 652 728 395 225 67% 21% 4% 100% 48% 11% 2% 3% 2% 4% 1% 5% 14%
Liver 6587 3129 2200 873 385 52% 32% 2% 14% 100% 7% 1% 1% 3% 6% 1% 1% 8%
Other G-I 909 230 317 221 141 75% 23% 3% 24% 50% 100% 5% 3% 2% 5% 1% 3% 16%
Urinary 
system 217 72 67 42 36 67% 19% 2% 18% 32% 19% 100% 3% 4% 5% 4% 1% 19%
Skin 168 40 47 38 43 76% 25% 2% 30% 42% 15% 4% 100% 5% 11% 1% 2% 23%
Nervous 
system 429 90 104 134 99 79% 54% 6% 7% 53% 5% 2% 2% 100% 17% 6% 1% 10%
Bone 717 145 203 203 166 80% 45% 4% 10% 59% 7% 1% 3% 10% 100% 4% 2% 16%
Adrenal 139 8 43 43 45 94% 55% 4% 12% 65% 6% 6% 1% 17% 19% 100% 1% 14%
Ovary 205 45 58 57 45 78% 22% 2% 47% 43% 14% 1% 2% 2% 7% 1% 100% 18%
Other 1126 373 250 288 215 67% 29% 4% 25% 50% 13% 4% 3% 4% 10% 2% 3% 100%
RECTUM
Lung 2591 550 1267 547 227 79% 100% 4% 6% 63% 6% 2% 1% 11% 14% 3% 0% 9%
Pleura/
Med. 156 11 43 55 47 93% 74% 100% 10% 58% 4% 4% 3% 13% 18% 3% 0% 15%
Peritoneum 461 115 155 124 67 75% 32% 3% 100% 52% 13% 3% 3% 2% 11% 2% 1% 15%
Liver 3898 1769 1354 556 219 55% 42% 2% 6% 100% 6% 1% 1% 5% 10% 2% 0% 7%
Other G-I 377 57 141 119 60 85% 38% 2% 15% 58% 100% 5% 2% 5% 13% 3% 1% 12%
Urinary 
system 115 13 28 45 29 89% 42% 5% 13% 43% 16% 100% 3% 11% 19% 8% 2% 31%
Skin 83 16 20 26 21 81% 46% 5% 16% 40% 10% 5% 100% 11% 22% 7% 1% 18%
Nervous 
system 442 75 129 142 98 83% 65% 5% 2% 46% 4% 3% 2% 100% 18% 7% 0% 13%
Bone 681 118 194 227 142 83% 54% 4% 7% 57% 7% 3% 3% 11% 100% 5% 0% 13%
Adrenal 108 8 19 28 53 93% 70% 5% 8% 58% 9% 8% 6% 30% 31% 100% 0% 15%
Ovary 34 11 8 11 4 68% 26% 0% 15% 41% 6% 6% 3% 3% 6% 0% 100% 24%
Other 602 37 293 168 104 94% 40% 4% 11% 43% 8% 6% 2% 9% 14% 3% 1% 100%
Table 4.  Location of metastases in patients with spread to one (N = 7,990) or more (N = 6,975) sites. 
Percentages indicate how many of all patients with site-specific metastases have multiple metastases also 
involving other sites.
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In summary, we provide reliable figures on the metastatic spread from colon and rectal cancer. Anatomical 
location and histological subtype profoundly affected the patterns of metastasis when considering organs beyond 
the liver: rectal cancer metastasized to the thorax, nervous system and bone, whereas colon cancer and mucinous 
and signet ring adenocarcinomas metastasized within the peritoneum. Several distinct combinations of meta-
static occurred with likely clues to the metastatic pathways. Prognosis in CRC patients with solitary metastases 
was worst in nervous system (4 months) and bone (5.5 months) metastases, intermediary in liver metastases (9 
months) and most favorable with thoracic metastases (14 months). The T and N stages were important predic-
tors of survival in CRC patients with solitary metastases. Careful surveillance of lung metastases in lower stage 
patients is warranted, most importantly in rectal cancer.
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